News Releases

News Releases

Date Title and Summary Additional Formats
Toggle Summary Clementia Pharmaceuticals Inc. Appoints Francois Nader, M.D. to Board of Directors
Healthcare Industry Veteran Brings Deep Expertise in Developing Innovative Therapies for Patients with Rare Diseases MONTREAL, CANADA, March 26, 2014 (Marketwired)  —  Clementia Pharmaceuticals Inc. , a privately held clinical-stage biotechnology company dedicated to serving those
View HTML
Toggle Summary Clementia Pharmaceuticals Inc. Announces Key Leadership Appointments
World-class team with extensive orphan drug and rare disease experience to advance palovarotene into clinical development for the treatment of FOP MONTREAL, CANADA, January 29, 2014 (Marketwired)  —  Clementia Pharmaceuticals Inc. , a privately held clinical stage biotechnology company
View HTML
Toggle Summary Clementia Pharmaceuticals Inc. Announces Closing of $22.5 Million Series A Financing With Preeminent U.S. and Canadian Healthcare Venture Capital Funds
Company licenses exclusive world-wide rights to palovarotene from Roche Pharmaceuticals OrbiMed and BDC Venture Capital investment to advance palovarotene into clinical development for the treatment of FOP MONTREAL, CANADA, January 9, 2014 (Marketwired)  —  Clementia Pharmaceuticals Inc.
View HTML